Travere Therapeutics Q4 Revenue Up 73.4%, EPS at $0.03 Beats Expectations
Travere Therapeutics reported Q4 revenues of $129.69 million, up 73.4% year-on-year, missing consensus estimates by 8.97%, while EPS was $0.03 versus a loss of $0.73. FILSPARI sales surged 108.2% to $103.34 million, and license revenue jumped 148.3% to $3.08 million.
1. Q4 Financial Summary
Travere Therapeutics generated $129.69 million in revenue for the quarter ended December 2025, marking a 73.4% increase from the prior year but falling 8.97% short of consensus estimates, while EPS rose to $0.03 from a loss of $0.73, exceeding forecast by 16.73%.
2. Product Segment Performance
Tiopronin products delivered $23.27 million in revenue versus $21.90 million estimated, a 2.6% year-on-year decline. Net product sales totaled $126.61 million, up 72.2% from a year ago against estimates of $125.35 million. FILSPARI contributed $103.34 million, up 108.2% versus projections of $103.05 million, and license and collaboration revenue reached $3.08 million, rising 148.3% year-over-year though below the $15.33 million forecast.
3. Share Performance and Outlook
Shares of Travere have declined 1.4% over the past month compared with a 0.8% drop in the broader market. The stock maintains a neutral rating, suggesting it may perform in line with industry benchmarks in the near term.